Status message

Active context: kki_bg_colors_yellow

Interventional, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of Vortioxetine in Adults with Attention Deficit Hyperactivity Disorder (ADHD)

Principal Investigator:
Robert
Findling

Primary Objective:

To evaluate the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on ADHD symptoms in the treatment of adult patients with a DSM-5™ diagnosis of ADHD.

Secondary Objectives:

  • To evaluate the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on:
    • Inattention (patient-reported outcome [PRO])
    • Overall functioning (PRO)
    • Emotional dysregulation (PRO)
    • ADHD symptoms (investigator-rated)
    • ADHD symptoms (PRO)
    • Cognitive function (PRO)
    • Global clinical impression (investigator-rated)
    • Productivity (PRO)
    • Health-related quality of life (PRO)

Additional Objectives:

  • To evaluate the population pharmacokinetics of vortioxetine in adult patients with ADHD and estimate individual oral clearance (CL/F) values
  • To evaluate the compliance with vortioxetine treatment for the individual patient based on the plasma concentrations and the estimated CL/F
  • To investigate associations between biomarkers and clinical features

Safety Objective:

To evaluate the safety and tolerability of vortioxetine 10 mg/day and 20 mg/day versus placebo in adult patients with a diagnosis of ADHD.

March is Brain Injury Awareness Month

Brain Injury Awareness Month

Help raise awareness and support for brain injury research, treatment and education. Learn more about our program.

Publications

Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.